NEW YORK, August 11, 2014 /PRNewswire/ --
Today, Analysts Review released its research reports regarding Amgen Inc. (NASDAQ: AMGN), Mylan, Inc. (NASDAQ: MYL), Biogen Idec Inc. (NASDAQ: BIIB), Perrigo Company PLC (NYSE: PRGO) and Zimmer Holdings, Inc. (NYSE: ZMH). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5618-100free.
--
Amgen Inc. Research Reports
On August 4, 2014, Amgen Inc. (Amgen) and its subsidiary, Onyx Pharmaceuticals, Inc., announced that a planned interim analysis demonstrated that the Phase III clinical trial ASPIRE (CArfilzomib, Lenalidomide, and DexamethaSone versus Lenalidomide and Dexamethasone for the treatment of Patients with Relapsed Multiple MyEloma) met its primary endpoint of progression-free survival. According to the Company, patients treated with Kyprolis (carfilzomib) for Injection in combination with Revlimid (lenalidomide) and low-dose dexamethasone (KRd) lived significantly longer without their disease worsening (median 26.3 months) compared to patients treated with Revlimid and low-dose dexamethasone (Rd) (median 17.6 months). According to Amgen, while the data for overall survival, a secondary endpoint, are not yet mature, the analysis showed a trend in favor of KRd that did not reach statistical significance. Amgen informed that it would submit the results for presentation at the 56th Annual Meeting of the American Society of Hematology, scheduled for December 6 to December 9, 2014, at Moscone Center, San Francisco, California. The full research reports on Amgen are available to downloadfree of charge at:
http://www.analystsreview.com/Aug-11-2014/AMGN/report.pdf
--
Mylan, Inc. Research Reports
On August 6, 2014, the shares of Mylan, Inc. fell 1.13% from its previous day's close to end the trading session at $47.92. The stock opened at $47.83, touched an intraday high of $48.04 and a low of $47.53. A total of 6.78 million changed hands, higher than the 30-day average trading volume of 4.80 million shares. The stock has 52-week low of $34.46 and a 52-week high of $57.52. Over the past 12-months, the stock has gained an upside of 31.65%, outperforming the NASDAQ Composite, which returned 18.04%, during the same time period. The full research reports on Mylan are available to download free of charge at:
http://www.analystsreview.com/Aug-11-2014/MYL/report.pdf
--
Biogen Idec Inc. Research Reports
On July 23, 2014, Biogen Idec Inc. (Biogen) announced that the European Commission (EC) has granted marketing authorization for PLEGRIDYTM (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). Biogen informed that PLEGRIDY is dosed once every two weeks and is administered subcutaneously with the PLEGRIDY PEN, a new ready-to-use autoinjector, or a prefilled syringe. Biogen informed that the EC approval of PLEGRIDY is based on results from one of the largest pivotal studies of a beta interferon conducted, ADVANCE1, which involved more than 1,500 patients with relapsing forms of MS. The full research reports on Biogen are available to download free of charge at:
http://www.analystsreview.com/Aug-11-2014/BIIB/report.pdf
--
Perrigo Company PLC Research Reports
On August 5, 2014, Sergeant's Pet Care Products, Inc, - a Perrigo Company PLC (Perrigo) group Company introduced SENTRY® Petrodex® advanced dental care calming kit for dogs. The Company stated that the product which is available at pet specialty retailers includes Triple Action Calming Toothpaste, a Dual-Ended Toothbrush and a Finger Toothbrush. "Our new SENTRY® Petrodex® Advanced Dental Care Calming Kit targets plaque and build up while helping to keep dogs calm while their teeth are brushed," said Caryn Stichler, Vice President of marketing, Sergeant's Pet Care Products, Inc. In another press release dated July, 31,2014, the Company informed that it will release its earnings for Q4 FY 2014 and full-year FY 2014 on August 14, 2014 at 8:00 a.m (ET), followed by a conference call at 10:00 a.m.(ET) hosted by Joseph C. Papa, Perrigo's Chairman, President and CEO. The full research reports onPerrigo are available to download free of charge at:
http://www.analystsreview.com/Aug-11-2014/PRGO/report.pdf
--
Zimmer Holdings, Inc. Research Reports
On July 24, 2014, Zimmer Holdings, Inc. (Zimmer) released its Q2 2014 financial results. Net sales increased 1.2% YoY to $1.2 billion (an increase of 0.9% YoY on constant currency). Net earnings were $176.5 million versus $152.1 million in Q2 2013, while adjusted net earnings increased 4.6% YoY to $254.7 million. Zimmer anticipates full-year 2014 revenues to increase between 2.0% and 3.0% YoY on a constant currency basis versus the prior range of 3% to 5% YoY. The Company revised its full-year 2014 diluted EPS guidance to be in a range of $4.65 to $4.75 from the prior guidance of $4.90 to $5.10. David Dvorak, President and CEO of Zimmer, said, "Our confidence in the opportunity to create value in the musculoskeletal market remains strong. In addition, we are excited about the progress we are making in working with the Biomet leadership team to plan our combination, and we continue to anticipate closing the merger in the first quarter of 2015." The full research reports on Zimmer are available to download free of charge at:
http://www.analystsreview.com/Aug-11-2014/ZMH/report.pdf
--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.
===============
EDITOR'S NOTES:
===============
1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.
2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.
5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.
6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
